{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:58:22Z","timestamp":1782741502499,"version":"3.54.5"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81300370"],"award-info":[{"award-number":["81300370"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018T110855"],"award-info":[{"award-number":["2018T110855"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Support Program","award":["2017M622650"],"award-info":[{"award-number":["2017M622650"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong","doi-asserted-by":"publisher","award":["2018A030313161"],"award-info":[{"award-number":["2018A030313161"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>TP53 mutation is one of the most common genetic changes in hepatocellular carcinoma (HCC). It is of great clinical significance to tailor specialized prognostication approach and to explore more therapeutic options for TP53-mutant HCCs. In this study, a total of 1135 HCC patients were retrospectively analyzed. We developed a random forest-based prediction model to estimate TP53 mutational status, tackling the problem of limited sample size in TP53-mutant HCCs. A multi-step process was performed to develop robust poor prognosis-associated signature (PPS). Compared with previous established population-based signatures, PPS manifested superior ability to predict survival in TP53-mutant patients. After in silico screening of 2249 drug targets and 1770 compounds, we found that three targets (CANT1, CBFB and PKM) and two agents (irinotecan and YM-155) might have potential therapeutic implications in high-PPS patients. The results of drug targets prediction and compounds prediction complemented each other, presenting a comprehensive view of potential treatment strategy. Overall, our study has not only provided new insights into personalized prognostication approaches, but also thrown light on integrating tailored risk stratification with precision therapy.<\/jats:p>","DOI":"10.1093\/bib\/bbaa164","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T11:07:25Z","timestamp":1593688045000},"source":"Crossref","is-referenced-by-count":214,"title":["Prognosis and personalized treatment prediction in <i>TP53<\/i>-mutant hepatocellular carcinoma: an <i>in silico<\/i> strategy towards precision oncology"],"prefix":"10.1093","volume":"22","author":[{"given":"Chen","family":"Yang","sequence":"first","affiliation":[{"name":"Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Huang","sequence":"additional","affiliation":[{"name":"Ministry of Health, Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfei","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Lv","sequence":"additional","affiliation":[{"name":"Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-3634","authenticated-orcid":false,"given":"Shixue","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, South China University of Technology, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2021052110285031000_ref1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021052110285031000_ref2","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"key":"2021052110285031000_ref3","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1038\/s41598-017-04811-5","article-title":"Development and validation of a three-gene prognostic signature for patients with hepatocellular carcinoma","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"2021052110285031000_ref4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12072-019-09962-3","article-title":"Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis","volume":"13","author":"Yan","year":"2019","journal-title":"Hepatol Int"},{"key":"2021052110285031000_ref5","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.ejca.2012.03.001","article-title":"Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis","volume":"48","author":"Liu","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021052110285031000_ref6","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1111\/jcmm.13863","article-title":"A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma","volume":"22","author":"Long","year":"2018","journal-title":"J Cell Mol Med"},{"key":"2021052110285031000_ref7","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/jcp.29081","article-title":"Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma","volume":"235","author":"Liu","year":"2020","journal-title":"J Cell Physiol"},{"key":"2021052110285031000_ref8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2021052110285031000_ref9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ebiom.2019.03.022","article-title":"Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma","volume":"42","author":"Long","year":"2019","journal-title":"EBioMedicine"},{"key":"2021052110285031000_ref10","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"Carcinoma","year":"2019","journal-title":"N Engl J Med"},{"key":"2021052110285031000_ref11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cell.2019.10.038","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"key":"2021052110285031000_ref12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-019-1607-3","article-title":"Inducing and exploiting vulnerabilities for the treatment of liver cancer","volume":"574","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"2021052110285031000_ref13","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng.3547","article-title":"Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer","volume":"48","author":"Fujimoto","year":"2016","journal-title":"Nat Genet"},{"key":"2021052110285031000_ref14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"2021052110285031000_ref15","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/bioinformatics\/btz851","article-title":"Somatic selection distinguishes oncogenes and tumor suppressor genes","volume":"36","author":"Chandrashekar","year":"2020","journal-title":"Bioinformatics"},{"key":"2021052110285031000_ref16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.cell.2014.07.027","article-title":"Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality","volume":"158","author":"Jerby-Arnon","year":"2014","journal-title":"Cell"},{"key":"2021052110285031000_ref17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.21467","article-title":"Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets","volume":"45","author":"Boyault","year":"2007","journal-title":"Hepatology"},{"key":"2021052110285031000_ref18","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"key":"2021052110285031000_ref19","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep.29254","article-title":"Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection","volume":"66","author":"Desert","year":"2017","journal-title":"Hepatology"},{"key":"2021052110285031000_ref20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/1878-0261.12639","article-title":"Metabolism-associated molecular classification of hepatocellular carcinoma","volume":"14","author":"Yang","year":"2020","journal-title":"Mol Oncol"},{"key":"2021052110285031000_ref21","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2021052110285031000_ref22","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"2021052110285031000_ref23","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.2147\/OTT.S121594","article-title":"Prognostic value of p53 mutation for poor outcome of Asian primary liver cancer patients: evidence from a cohort study and meta-analysis of 988 patients","volume":"9","author":"Wen","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2021052110285031000_ref24","first-page":"260","article-title":"TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis","volume":"2","author":"Zhan","year":"2013","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2021052110285031000_ref25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/1541-7786.MCR-15-0403","article-title":"Hypermutation of DPYD deregulates pyrimidine metabolism and promotes malignant progression","volume":"14","author":"Edwards","year":"2016","journal-title":"Mol Cancer Res"},{"key":"2021052110285031000_ref26","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.ajpath.2010.12.046","article-title":"The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro","volume":"178","author":"Gerhardt","year":"2011","journal-title":"Am J Pathol"},{"key":"2021052110285031000_ref27","doi-asserted-by":"crossref","first-page":"22635","DOI":"10.1002\/jcp.28829","article-title":"Calcium-activated nucleotidase 1 silencing inhibits proliferation, migration, and invasion in human clear cell renal cell carcinoma","volume":"234","author":"Liu","year":"2019","journal-title":"J Cell Physiol"},{"key":"2021052110285031000_ref28","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/s41467-019-10102-6","article-title":"The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription","volume":"10","author":"Malik","year":"2019","journal-title":"Nat Commun"},{"key":"2021052110285031000_ref29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41375-019-0605-7","article-title":"Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice","volume":"34","author":"Saida","year":"2020","journal-title":"Leukemia"},{"key":"2021052110285031000_ref30","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/jcp.22298","article-title":"Association of core-binding factor beta with the malignant phenotype of prostate and ovarian cancer cells","volume":"225","author":"Davis","year":"2010","journal-title":"J Cell Physiol"},{"key":"2021052110285031000_ref31","first-page":"1535","article-title":"PKM2 knockdown induces autophagic cell death via AKT\/mTOR pathway in human prostate cancer cells","volume":"52","author":"Dey","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"2021052110285031000_ref32","doi-asserted-by":"crossref","first-page":"152409","DOI":"10.1016\/j.prp.2019.04.001","article-title":"Pyruvate kinase M2 contributes to cell growth in gastric cancer via aerobic glycolysis","volume":"215","author":"Li","year":"2019","journal-title":"Pathol Res Pract"},{"key":"2021052110285031000_ref33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"2021052110285031000_ref34","first-page":"5077","article-title":"Tumor type M2 pyruvate kinase expression in advanced breast cancer","volume":"20","author":"Luftner","year":"2000","journal-title":"Anticancer Res"},{"key":"2021052110285031000_ref35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.18632\/oncotarget.278","article-title":"No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis","volume":"2","author":"Bluemlein","year":"2011","journal-title":"Oncotarget"},{"key":"2021052110285031000_ref36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.semcancer.2005.04.009","article-title":"Pyruvate kinase type M2 and its role in tumor growth and spreading","volume":"15","author":"Mazurek","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"2021052110285031000_ref37","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/bjc.2017.55","article-title":"Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1","volume":"116","author":"Xu","year":"2017","journal-title":"Br J Cancer"},{"key":"2021052110285031000_ref38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/jgo.2016.09.07","article-title":"Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"2021052110285031000_ref39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/1097-0142(20010101)91:1<101::AID-CNCR13>3.0.CO;2-K","article-title":"A phase II study of irinotecan in patients with advanced hepatocellular carcinoma","volume":"91","author":"O'Reilly","year":"2001","journal-title":"Cancer"},{"key":"2021052110285031000_ref40","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejca.2005.09.034","article-title":"Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level","volume":"42","author":"Boige","year":"2006","journal-title":"Eur J Cancer"},{"key":"2021052110285031000_ref41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1254\/jphs.FP0070442","article-title":"Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis","volume":"104","author":"Takeba","year":"2007","journal-title":"J Pharmacol Sci"},{"key":"2021052110285031000_ref42","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.18632\/oncotarget.3337","article-title":"The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma","volume":"6","author":"Xia","year":"2015","journal-title":"Oncotarget"},{"key":"2021052110285031000_ref43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.leukres.2010.11.016","article-title":"Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma","volume":"35","author":"Kita","year":"2011","journal-title":"Leuk Res"},{"key":"2021052110285031000_ref44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2010.12.007","article-title":"Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells","volume":"302","author":"Wang","year":"2011","journal-title":"Cancer Lett"},{"key":"2021052110285031000_ref45","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","article-title":"Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer","volume":"27","author":"Giaccone","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/3\/bbaa164\/37965511\/bbaa164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/3\/bbaa164\/37965511\/bbaa164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T10:29:22Z","timestamp":1621592962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbaa164\/5891146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaa164","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5]]},"published":{"date-parts":[[2020,8,13]]},"article-number":"bbaa164"}}